LENZ Therapeutics, Inc. Annual Report: 2025 Performance

This guide breaks down how LENZ Therapeutics performed in 2025. Use this "cheat sheet" to decide if the company fits your investment goals.

1. What does this company do?

LENZ Therapeutics has transitioned from a research-focused lab to a commercial business. Their flagship product, VIZZ® (aceclidine), is a daily, preservative-free eye drop for presbyopia—the age-related loss of near vision. VIZZ constricts the pupil to improve focus without the side effects often associated with older, pilocarpine-based competitors. The company currently distributes this product across the U.S. through a specialized pharmacy network.

2. The Big Shift: From Testing to Selling

The major milestone for 2025 was the FDA approval of VIZZ® on July 31, 2025. Following the launch in August, the product reached retail pharmacies nationwide by November. The company is targeting a significant share of the $3 billion presbyopia treatment market, which serves an estimated 128 million Americans.

3. Business Strategy: The "Self-Pay" Model

LENZ is bypassing the complex insurance reimbursement process by positioning VIZZ as a "self-pay" product. This strategy avoids the multi-year struggle of negotiating with insurance middlemen, allowing for immediate revenue and direct control over pricing. Their marketing efforts are concentrated on the 15,000 eye doctors who write 80% of all presbyopia prescriptions in the U.S.

4. Financial Health

At the end of 2025, LENZ held $215 million in cash and investments, providing a runway to fund operations into 2027. While the company is generating revenue, it continues to report a loss as it funds its initial commercial launch. They carry no long-term debt and are utilizing current cash reserves to reach profitability. The leadership team, including CEO Eef Schimmelpennink, brings experience from building blockbuster brands like Botox at Allergan.

5. Key Risks

• Competition: The market is crowded. LENZ competes against established brands like AbbVie’s Vuity, Orasis Pharmaceuticals’ Qlosi, and Yuvezzi. These rivals possess larger marketing budgets and existing relationships with eye care providers.
• Single-Asset Risk: The company relies entirely on the success of VIZZ. If the product fails to gain sufficient market share or encounters safety concerns, the company’s valuation could be negatively impacted.
• Cash Burn and Dilution: The company is investing heavily in the "Make It VIZZable" marketing campaign. If sales targets are not met, the company may need to raise additional capital through equity offerings, which would dilute current shareholders.

6. Future Outlook

LENZ is currently in a growth phase. Their primary objective for 2026 is to scale U.S. sales and optimize their pharmacy distribution network. Additionally, they are pursuing international licensing deals to expand VIZZ into European and Asian markets. With U.S. patent protection extending until 2044, the company maintains a long-term competitive advantage, provided they can successfully drive patient adoption.

---

Investor Takeaway: LENZ is a classic "show me" stock. They have successfully moved from clinical trials to a commercial product, but their success now depends entirely on their ability to win market share in a crowded space without the help of insurance coverage. Keep a close eye on their quarterly sales reports to see if their marketing spend is effectively turning into consistent revenue.